Clinical trial
Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer
NCT00039442 · Gynecologic Oncology Group, Other · Completed
Key facts
| NCT number | NCT00039442 |
|---|---|
| Title | Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer |
| Official title | A Phase II Evaluation Of Capecitabine (NSC #712807) In The Treatment Of Persistent Or Recurrent Non-Squamous Cell Carcinoma Of The Cervix |
| Lead sponsor | Gynecologic Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Recurrent Cervical Carcinoma |
| Intervention type | Drug, Other |
| Interventions | Capecitabine, Laboratory Biomarker Analysis |
| Enrollment | 21 |
| Start date | Apr 29, 2002 |
| Primary completion | Dec 7, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Aug 24, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: